Awardees will receive $330,000 grants co-funded by Yosemite and the American Cancer Society to pursue critical cancer ...
Discover how UCSF is leading the charge in Long COVID research, uncovering key findings that advance our understanding of the condition. UCSF researchers have adapted innovative tools and ...
A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment, Memorial ...
The site, which will cost about €10.0 billion ($11.7 billion) to complete, will be the third-largest of the company’s Verbund ...
Zacks Small Cap Research on MSN
YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations
By Brad Sorensen, CFA NASDAQ:YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and regenerative ophthalmology under a single commercial ...
SHANGHAI and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the ...
Everyday Health on MSN
We asked RDs to share their favorite turmeric supplements — these 6 top the list
Boost your wellness routine with these RD-approved turmeric supplements. Whether it's capsules, gummies, or powder, discover the best choice for your lifestyle.
Roy Mathew, MD, discusses integrating nephrology and cardiology to bridge the gap in patient adherence and care delivery. While the pipeline for cardio-renal therapeutics is expanding, clinical ...
10d
How Leading Plywood Manufacturers are Redefining Themselves in the Modern Building Materials Arena
This has led to a clear industry-wide strategy: leverage core competencies in supply chain, manufacturing, and B2B ...
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on ...
SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ...
The New Year’s Eve champagne isn’t even warm yet, and CES week is already upon us. The giant annual celebration of consumer tech kicks off the first full week of January as companies across the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback